Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860879 | 0.83 | CYP2D6 (0.61) | MAPTHSD17B10NPC1EGFRERBB2 | |
| SCHEMBL11070346 | 0.78 | L3MBTL1 (0.63) | KMT2AMAPTNPC1GFERSLC1A2 | |
| SCHEMBL13242349 | 0.76 | MAPT (0.76) | KMT2AMAPTHSD17B10NPC1GFER | |
| SCHEMBL20419342 | 0.75 | GFER (0.79) | KMT2AMAPTHSD17B10GFERL3MBTL1 | |
| SCHEMBL18840962 | 0.75 | CCR3 (1.00) | CCR3MAPTTHRBALDH1A1 | |
| SCHEMBL24336168 | 0.75 | GFER (0.56) | CCR3KMT2AMAPTTHRBHSD17B10 | |
| SCHEMBL6153220 | 0.74 | ALDH1A1 (0.66) | KMT2AMAPTNPC1SLC1A2L3MBTL1 | |
| SCHEMBL6071110 | 0.74 | SIGMAR1 (0.56) | KMT2AMAPTL3MBTL1SIGMAR1HTT | |
| SCHEMBL13242339 | 0.73 | KMT2A (0.74) | KMT2AMAPTHSD17B10NPC1SLC1A2 | |
| SCHEMBL11071924 | 0.72 | KMT2A (0.71) | KMT2AMAPTNPC1GFERL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6991902-B2 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6893815-B1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-1999000669-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | PNP, ATIC, DPYD | CCR3 1011/4885KMT2A 3591/4885MAPT 4034/4885 |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | PNP, ATIC, DPYD | CCR3 1011/4885KMT2A 3591/4885MAPT 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.